Relationship between native papillary muscle T1 time and severity of functional mitral regurgitation in patients with non-ischemic dilated cardiomyopathy

Table 1 Characteristics of study subjects

	DCM MR (+), N = 22	DCM MR (-), N = 18	Controls, N = 20	* P-value DCM MR (+) vs DCM MR (-)	* P-value DCM MR (+) vs Controls	* P-value DCM MR (-) vs Controls
Demographics
Male, %	15 (68 %)	16 (89 %)	13 (65 %)	0.12	0.83	0.083
Age, years	52 ± 16	58 ± 13	54 ± 13	0.32	0.98	0.44
Height, cm	176 ± 9	175 ± 8	172 ± 8	0.99	0.41	0.52
Body weight, kg	93 ± 20	86 ± 15	79 ± 15	0.47	0.10	0.67
BMI, kg	30 ± 7	28 ± 6	27 ± 4	0.51	0.21	0.86
BSA, m²	2.1 ± 0.3	2.0 ± 0.2	1.9 ± 0.2	0.58	0.10	0.57
SBP, mmHg	116 ± 14	119 ± 17	119 ± 12	0.80	0.70	0.99
DBP, mmHg	70 ± 11	74 ± 14	71 ± 10	0.53	0.70	0.59
Heart rate, bpm	76 ± 12	73 ± 12	68 ± 14	0.77	0.14	0.47
Medications
Aspirin	7 (32 %)	7 (39 %)	-	0.64	-	-
ACE/ARBs	18 (82 %)	16 (89 %)	-	0.38	-	-
Calcium channel blockers	2 (9 %)	2 (11 %)	-	0.83	-	-
Beta blockers	17 (77 %)	14 (78 %)	-	0.97	-	-
Diuretics	11 (50 %)	7 (39 %)	-	0.48	-	-
Aldosterone inhibitors	2 (9 %)	1 (6 %)	-	0.67	-	-
Statin	9 (41 %)	9 (50 %)	-	0.57	-	-
Warfarin	5 (8 %)	2 (11 %)	-	0.90	-	-

*P value was calculated by one-way ANOVA with Tukey’s correction or Chi-square test
ACE angiotensin converting enzyme inhibitor, ANOVA analysis of variance, ARB angiotensin receptor blocker, BMI body mass index, BSA body surface area, DBP diastolic blood pressure, DCM dilated cardiomyopathy, HR heart rate, MR mitral regurgitation, SBP systolic blood pressure

ISSN: 1532-429X